Spectrum Pharmaceuticals Inc. (Nasdaq: SPPI) reported positive updated data for a Phase 2 study of posiotinib in EGFR Exon 20 Mutant Non-Small Cell Lung Cancer sending the stock price soaring $6.13 to close at $20.76.
Spectrum Pharmaceuticals reports positive update data
April 10, 2018 at 17:28 PM EDT
